One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2020-134851
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2020 |
 Citations: 8 |
Affiliation: University of Bologna, The University of Texas MD Anderson Cancer Center, European Institute of Oncology, Hackensack University Medical Center, Rocky Mountain Cancer Centers, University of Maryland, Baltimore, Medical University of Silesia, Compass Oncology, The Maria Sklodowska-Curie National Research Institute of Oncology, CDG Therapeutics (United States), Levine Cancer Institute, Georgetown University, Fort Wayne Medical Institute, Swedish Medical Center, Willamette Valley Cancer Institute and Research Center, Florida Cancer Specialists & Research Institute, Instytut Hematologii i Transfuzjologi, University Hospitals Seidman Cancer Center, Moffitt Cancer Center, Stocznia Gdynia (Poland), University of Cambridge, Columbia University Irving Medical Center, Sarah Cannon, Michigan Center for Translational Pathology, University of Michigan–Ann Arbor, Sir Charles Gairdner Hospital, Linear Clinical Research
Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
